Nucana Stock Price, News & Analysis

NuCana plc (NASDAQ: NCNA) presented two significant posters at the AACR Annual Meeting on April 14-19, 2023, showcasing its investigational drug NUC-7738. The first study demonstrated a reduction in soluble and exosomal PD-L1 in melanoma cell lines and patients, indicating potential as an immune sensitizer in combination with pembrolizumab. The second study illustrated NUC-7738's ability to decrease glutaminase GAC isoform in cancer tissues, suggesting anti-cancer activity in highly metabolic tumors. CEO Hugh S. Griffith expressed optimism about NUC-7738's mechanisms of action and ongoing clinical studies, particularly its combination therapy approach. NuCana aims to enhance treatment outcomes for cancer patients using its ProTide technology.

NuCana plc (NASDAQ: NCNA) reported its Q4 and full-year 2022 financial results, revealing a cash position of £41.9 million, down from £50.8 million in Q3 2022. The company faced a net loss of £15.2 million for Q4 2022 compared to £13.6 million in Q4 2021, and an annual net loss of £32.0 million, improving from £40.5 million in 2021. Loss per share was £0.29 for Q4 and £0.61 for FY 2022. CEO Hugh S. Griffith highlighted significant progress in their ProTide therapeutics, with important data readouts expected in 2023 for NUC-3373 and NUC-7738. The company anticipates a cash runway through 2025, supporting ongoing clinical trials and development efforts.

NuCana plc (NASDAQ: NCNA) announced that the European Patent Office's Technical Board of Appeal ruled that its European Patent 2955190 is not valid. The decision reverses earlier validations from 2021 and a judgment in the UK on March 21, 2023, which also deemed the patent invalid. Despite this setback, NuCana emphasized that it will not impair its anti-cancer ProTide therapies, as they are protected by other patents. CEO Hugh S. Griffith reassured stakeholders that the company remains financially stable, with all clinical programs on track and multiple data announcements expected in 2023.

NuCana plc (Nasdaq: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will participate in two coming investor conferences. The first is Cowen’s 43rd Annual Healthcare Conference on March 7, 2023, at 10:30 AM ET, and the second is Oppenheimer's 33rd Annual Healthcare Conference on March 14, 2023, at 12:40 PM ET. Both presentations will be available for live webcast and replay in the Investors section of the company's website.

NuCana is focused on enhancing cancer treatments via its ProTide technology, with key products NUC-3373 and NUC-7738 undergoing various clinical trials. The company aims to improve patient outcomes with these advancements.

NuCana plc (NASDAQ: NCNA) announced it has regained compliance with Nasdaq's minimum bid price requirement, having maintained a closing bid price of $1.00 or more for 10 consecutive business days from January 5 to January 19, 2023. Previously, the company was notified on January 6, 2023, that its American Depositary Shares (ADSs) had fallen below the $1.00 threshold for over 30 days. The Notification Letter confirms that the matter is now resolved. NuCana focuses on enhancing cancer treatment outcomes through its ProTide technology, with ongoing clinical studies for its drug candidates NUC-3373 and NUC-7738.

NuCana plc (NASDAQ: NCNA) received a Notification Letter from Nasdaq on January 3, 2023, indicating that the company's American Depositary Shares (ADSs) have fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days.

The notification does not affect the current listing of ADSs, which will continue to trade on Nasdaq. NuCana has a 180-day grace period, until July 3, 2023, to regain compliance by maintaining a share price of $1.00 or higher for 10 consecutive days. Failing to do so may lead to a transfer to Nasdaq Capital Market.

NuCana plc (NASDAQ: NCNA) will participate in the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco, holding one-on-one meetings. The company focuses on enhancing cancer treatment outcomes via its proprietary ProTide technology, converting standard chemotherapy agents into safer medicines. NuCana's pipeline includes NUC-3373 for metastatic colorectal cancer and NUC-7738 for advanced solid tumors, both undergoing various phases of clinical trials.